Literature DB >> 20450755

[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome].

Gui-hua Gao1, Yun-xia Cao, Long Yi, Zhao-lian Wei, Yu-ping Xu, Chi Yang.   

Abstract

OBJECTIVE: To investigate the association between polymorphism of cytochrome P450 subfamily XIA polypeptide 1 (CYP11A1) gene and polycystic ovarian syndrome (PCOS) in Chinese population.
METHODS: From May 2005 to Dec. 2008, 290 PCOS cases treated in the First affiliated hospital of Anhui Medical University matched with 344 reproductive women as controls were enrolled in this study. Genotypes of 7 tagging single nucleotide polymorphisms (tSNP, rs12438594, rs4077582, rs9806234, rs16968477, rs4887139, rs1843090, rs11632698) covering CYP11A1 gene (r(2) > or = 0.8) and 3 microsatellite markers (D15S1547, D16S520, D15S1546) were chosed from the phase II database of Han population in HapMap data. Genotype and frequency of allele were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and haplotype of gene polymorphism were analyzed in 290 PCOS cases and 344 controls.
RESULTS: Among 7 tSNPs and 3 microsatellite markers, the frequency of rs4077582, D15S1547, D15S1546 and rs11632698 between two groups reached statistical difference (P = 0.010, 0.044, 0.018 and 0.026). The allele frequency of rs4077582, rs4887139, rs1843090, D15S1547 and D16S520 showed significant difference between two groups (P = 0.002, 0.048, 0.030, 0.001 and 0.024). Among 5 haplotype of CYP11A1 (ACGCA13/6/9AG, ACGTA16/6/11AA, GCACG12/8/8AA, GTACA14/4/7GG, GTGCA13/6/7AG), the frequency of GTACA14/4/7GG and ACGCA13/6/9AG were 7.8% (45/580) and 25.3% (147/580) in PCOS group and 11.9% and 19.6% in control group, which showed statistical difference (P < 0.05). There was no significant difference in the level of serum androgen at difference genotype from rs4077582 between two groups (P > 0.05).
CONCLUSION: The polymorphism of CYP11A1 gene was associated with PCOS, however, the relationship between gene sequence covered by tSNP/microsatellite markers and hyperandrogenism of PCOS should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450755

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  6 in total

1.  Polymorphisms of pentanucleotide repeats (tttta)n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis.

Authors:  Min Yu; Ruizhi Feng; Xiaoxi Sun; Haojue Wang; Huan Wang; Qing Sang; Li Jin; Lin He; Lei Wang
Journal:  Mol Biol Rep       Date:  2014-03-09       Impact factor: 2.316

2.  CYP11A1 microsatellite (tttta)n polymorphism in PCOS women from South India.

Authors:  K Ranjith Reddy; M L N Deepika; K Supriya; K Prasanna Latha; S S Lakshmana Rao; V Usha Rani; P Jahan
Journal:  J Assist Reprod Genet       Date:  2014-05-04       Impact factor: 3.412

3.  Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women.

Authors:  Cheng-Wei Zhang; Xin-Lin Zhang; Yan-Jie Xia; Yun-Xia Cao; Wen-Jun Wang; Pei Xu; Ye-Na Che; Xiao-Ke Wu; Long Yi; Qian Gao; Yong Wang
Journal:  Mol Biol Rep       Date:  2012-06-15       Impact factor: 2.316

4.  Risk-association of CYP11A1 polymorphisms and breast cancer among Han Chinese women in Southern China.

Authors:  Minying Sun; Xuexi Yang; Changsheng Ye; Weiwen Xu; Guangyu Yao; Jun Chen; Ming Li
Journal:  Int J Mol Sci       Date:  2012-04-18       Impact factor: 6.208

Review 5.  Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology.

Authors:  Roshan Dadachanji; Nuzhat Shaikh; Srabani Mukherjee
Journal:  Genet Res Int       Date:  2018-02-18

6.  In-Silico Investigation of Effects of Single-Nucleotide Polymorphisms in PCOS-Associated CYP11A1 Gene on Mutated Proteins.

Authors:  Fatima Muccee; Osama Bijou; Steve Harakeh; Rabi'atul Adawiyah; R Z Sayyed; Leila Haghshenas; Dikhnah Alshehri; Mohammad Javed Ansari; Shakira Ghazanfar
Journal:  Genes (Basel)       Date:  2022-07-12       Impact factor: 4.141

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.